ZLZhen Liu

Zhen Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhen Liu has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Jiuda Zhao

    Research Center for High Altitude Medicine, Key Laboratory of High Altitude Medicine (Ministry of Education), Key Laboratory of Application and Foundation for High Altitude Medicine Research in Qinghai Province (Qinghai-Utah Joint Research Key Lab for High Altitude Medicine), Laboratory for High Altitude Medicine of Qinghai Province, Qinghai University, Xining, China

    13 shared publications
  • Guoshuang Shen

    Breast Disease Diagnosis and Treatment Center of Qinghai University Affiliated Hospital & Affiliated Cancer Hospital of Qinghai University, Xining, China

    12 shared publications
  • Fuxing Zhao

    Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, China

    9 shared publications
  • Dengfeng Ren

    Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University, Xining, People’s Republic of China

    7 shared publications
  • Xingfa Huo

    Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, China

    5 shared publications
  • Yi Zhao

    The Center of Breast Disease Diagnosis and Treatment of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining 810000, China

    4 shared publications

Latest Publications

  • Open Access

    Breast cancer-related lymphedema of the upper limb: integrating early surveillance and functional surgery into a synergistic management paradigm

    by Tao Wu, Baixin Li, Bingyang Ma, Fuxing Zhao, Yan Li, Zhen Liu

    Breast cancer-related lymphedema (BCRL) of the upper limb is a chronic complication of breast cancer treatment that significantly impairs patient quality of life. Conventional management typically begins only after overt swelling occurs. This reactive approach delays diagnosis, relies on subjective assessment, and prioritizes volume reduction over functional recovery. Consequently, it often misses the optimal window for intervention. Recent advances in objective early-monitoring technologies, such as hyperspectral imaging and bioelectrical impedance analysis, alongside the development of precision functional lymphatic surgery, are now transforming BCRL care. This article details a novel “Precision Collaborative Management” paradigm, which integrates these diagnostic and surgical advances into a synergistic cycle where monitoring informs clinical decisions and surgical outcomes refine subsequent strategies. This paradigm establishes a continuous management pathway encompassing risk screening, early warning, precise intervention, and long-term follow-up across the entire disease continuum. Through sustained exploration in the aforementioned directions, we aim to transform BCRL management from a reactive symptom treatment to a proactive health safeguard, ultimately empowering breast cancer survivors to achieve a comprehensive and high-quality life. The paradigm facilitates a fundamental shift in BCRL clinical practice from delayed symptomatic treatment to early, function-preserving care.


  • Global research trends and hotspots in breast cancer related fatigue: a bibliometric investigation

    by Zhen Liu, Tao Wu, Weiwei Zhang, Jinming Li, Fuxing Zhao, Guoshuang Shen, Jiuda Zhao

    Background Cancer-related fatigue (CRF) is a common and debilitating issue for patients with breast cancer, significantly impacting quality of life and treatment efficacy. Despite the proliferation of multidisciplinary research, a comprehensive quantitative synthesis is still lacking. Such a synthesis would delineate global research trends, collaborative networks, and thematic evolution in this field. A comprehensive bibliometric analysis is therefore needed to map the scientific landscape, identify knowledge gaps, and inform future research directions. Methods To map the scientific landscape of cancer-related fatigue in breast cancer, this study extracted relevant publications from the Web of Science Core Collection (WOSCC) spanning from 2000 to 2024. The subsequent bibliometric analysis was conducted using specialized tools including VOSviewer, CiteSpace, and the R package “Bibliometrix” to meticulously chart the evolving trends and collaborative networks within this field. Results This study analyzed 4,549 documents from 56 countries, among which the United States leads in terms of scientific research output. Since 2015, the number of annual papers on CRF in breast cancer has continued to increase. The University of Texas MD Anderson Cancer Center was the most productive institution, and Supportive Care in Cancer published the highest number of related articles. The Journal of Clinical Oncology received the highest citation count. Christine Miaskowski was the most prolific author, and Julienne E. Bower was the most frequently co-cited researcher. Emerging research hotspots include keywords such as “patient-reported outcome measures”, “quality of life”and “cancer-related fatigue”. Conclusion This study offers a foundational resource for scholars investigating the evolving landscape of breast cancer-related fatigue research, underscoring ‘quality of life’ and ‘intervention’ as critical priorities and pivotal directions for future inquiry.

  • Development and validation of a machine learning model to predict moderate-to-severe cancer-related fatigue in breast cancer

    by Zhen Liu, Guoshuang Shen, Miaozhou Wang, Jiabin Wang, Yongxin Li, Jiuda Zhao

    Purpose This study aimed to establish and validate a machine learning model for predicting moderate-to-severe cancer-related fatigue (CRF) 2 years after completion of anti-tumor therapy in breast cancer patients. Methods Clinical and laboratory data from 183 patients were retrospectively collected. Candidate predictors were screened using multivariate logistic regression, and seven algorithms—logistic regression, decision tree, random forest, support vector machine, extreme gradient boosting (XGBoost), k-nearest neighbor, and naïve Bayes—were constructed in the training cohort and validated in the testing cohort. Model performance was assessed by discrimination, calibration, and decision curve analysis. Results The 2-year incidence of moderate-to-severe CRF was 54.0%. Eight independent predictors were identified, including age, body mass index, histological grade, menopausal status, hemoglobin, platelet count, neutrophil count, and systemic immune-inflammation index. Models built on these features demonstrated variable performance, with XGBoost showing the most favorable balance. It achieved an AUC of 0.983 in the training set and 0.766 in the validation set, with robust accuracy, sensitivity, and specificity. Calibration plots indicated good agreement between predicted and observed risks, while decision curve analysis confirmed higher net clinical benefit across a wide range of thresholds. Conclusion The XGBoost-based model provided reliable long-term CRF risk prediction, supporting early identification of high-risk patients and informing personalized survivorship care.


  • Open Access

    Effect of body mass index on postoperative lymphedema after breast cancer: a systematic review and meta-analysis

    by Weiwei Zhang, Zhilin Liu, Jinming Li, Hengheng Zhang, Meijie Wu, Ping Yang, Tao Wu, Guoshuang Shen, Fuxing Zhao, Zhen Liu

    Background Upper extremity lymphedema, a major complication post-breast cancer surgery, severely impacts quality of life. While body mass index (BMI) is suggested as a risk factor for postoperative breast cancer-related lymphedema (BCRL), evidence is inconsistent. This meta-analysis systematically evaluates BMI’s impact on postoperative lymphedema to resolve discrepancies and provide accurate insights. Methods The authors conducted comprehensive literature searches from inception to October 7, 2024, in major English-language databases, including PubMed, Embase, and Cochrane. To assess the association between BMI and postoperative BCRL, odds ratio (OR) with 95% confidence intervals (95% CI) were calculated. Subgroup analyses were also performed to evaluate the impact of BMI on postoperative lymphedema in breast cancer patients across different geographic regions. Results This meta-analysis included 16 studies involving 6,057 postoperative breast cancer patients, with sample sizes ranging from 101 to 1,130. The results revealed a significant association between elevated BMI and postoperative BCRL, with an OR of 2.05 (95% CI, 1.53–2.75; P < 0.005) for patients with BMI ≥ 25 kg/m² compared to those with BMI < 25 kg/m². These findings underscore a significant positive correlation between higher BMI and an increased risk of postoperative lymphedema in breast cancer patients. Conclusions Our findings demonstrate that a BMI ≥ 25 kg/m² is a significant risk factor for postoperative lymphedema in breast cancer patients. A comprehensive understanding of BMI’s role in lymphedema development post-surgery can inform clinicians and therapists in designing personalized strategies to mitigate this complication.


  • Open Access

    Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial

    by Guoshuang Shen, Zhilin Liu, Miaozhou Wang, Yi Zhao, Xinlan Liu, Yujin Hou, Wenbiao Ma, Jingqi Han, Xiaofeng Zhou, Dengfeng Ren, et al.

    We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative breast cancer (TNBC). In the phase 2 NeoSAC trial, patients with early TNBC received six cycles of apatinib, sintilimab, nab-paclitaxel, and carboplatin followed by surgery. The primary endpoint was pathological complete response (pCR) rate. Specimens collected pre-neoadjuvant therapy and post-surgery were retained for comprehensive analysis of predictive biomarkers and the impact on the tumor microenvironment. Among 34 enrolled patients, 24 achieved pCR (70.6%; 95% confidence interval (CI), 53.0-85.3), and 79.4% (95% CI, 65.1-93.7) had residual cancer burden 0-I. Imaging evaluation showed 21 complete responses (61.8%) and 13 partial responses (38.2%). The most common grade 3-4 adverse events were leukopenia (47%), neutropenia (36%), and thrombocytopenia (24%). The 36-month disease-free survival rate stood at 94.1% with a median follow-up of 39.1 months. Notably, baseline high ImmuneScore, immune cell infiltration, and enrichment of interferon-related pathways correlated with pCR. Comparison of pre-neoadjuvant and post-surgery data revealed that the pCR group treated with this novel regimen exhibited an upregulation of distinct immune cell subsets, thereby activating the tumor microenvironment. Moreover, higher oxeiptosis scores were associated with an increased likelihood of achieving pCR. Following neoadjuvant therapy, the pCR group showed a decrease in oxeiptosis score, whereas the non-pCR group exhibited an increase. Our study suggests that apatinib, sintilimab combined with carboplatin and nab-paclitaxel chemotherapy showed a promising clinical activity and manageable safety profile in early TNBC and merits further study. ClinicalTrials.gov registration: NCT04722718.


  • Open Access

    Prognostic nomograms for young breast cancer: A retrospective study based on the SEER and METABRIC databases

    by Yongxin Li, Xinlong Tao, Yinyin Ye, Yuyao Tang, Zhengbo Xu, Yaming Tian, Zhen Liu, Jiuda Zhao

    Background: Young breast cancer (YBC) is a subset of breast cancer that is often more aggressive, but less is known about its prognosis. In this study, we aimed to generate nomograms to predict the overall survival (OS) and breast cancer‐specific survival (BCSS) of YBC patients.Methods: Data of women diagnosed with YBC between 2010 and 2020 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The patients were randomly allocated into a training cohort (n = 15,227) and internal validation cohort (n = 6,526) at a 7:3 ratio. With the Cox regression models, significant prognostic factors were identified and used to construct 3‐, 5‐, and 10‐year nomograms of OS and BCSS. Data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) database were used as an external validation cohort (n = 90).Results: We constructed nomograms incorporating 10 prognostic factors for OS and BCSS. These nomograms demonstrated strong predictive accuracy for OS and BCSS in the training cohort, with C‐indexes of 0.806 and 0.813, respectively. The calibration curves verified that the nomograms have good prediction accuracy. Decision curve analysis demonstrated their practical clinical value for predicting YBC patient survival rates. Additionally, we provided dynamic nomograms to improve the operability of the results. The risk stratification ability assessment also showed that the OS and BCSS rates of the low‐risk group were significantly better than those of the high‐risk group.Conclusions: Here, we generated and validated more comprehensive and accurate OS and BCSS nomograms than models previously developed for YBC. These nomograms can help clinicians evaluate patient prognosis and make clinical decisions.


  • Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis

    by Ping Yang, Guoshuang Shen, Hengheng Zhang, Chengrong Zhang, Jinming Li, Fuxing Zhao, Zitao Li, Zhen Liu, Miaozhou Wang, Jiuda Zhao, et al.


  • Screening Single Nucleotide Polymorphisms Predicting the Efficacy of Electroacupuncture for Fatigue Treatment in Patients with Breast Cancer Following Adjuvant Chemotherapy

    by Fuxing Zhao, Guoshuang Shen, Dengfeng Ren, Miaozhou Wang, Zhen Liu, Yi Zhao, Qiqi Xie, Zhilin Liu, Zitao Li, Lihong Gao, et al.

    Chemotherapy-induced fatigue reduces not only the quality of life of patients but also effect their recurrence-free survival rate. Although electroacupuncture can relieve fatigue, it has limited affect on some patients. Therefore, appropriate biomarkers are needed to help screen patients who can benefit from electroacupuncture treatment of fatigue. We conducted this study to explore the predictive ability of SNPs on the efficacy of electroacupuncture in the treatment of fatigue in patients with breast cancer after adjuvant chemotherapy. Our study included breast cancer patients with fatigue after receiving paclitaxel and/or anthracycline based adjuvant chemotherapy. The patients were divided into the electroacupuncture group and the control group. The electroacupuncture treatment group received adjuvant chemotherapy and electroacupuncture treatment, while the control group only received adjuvant chemotherapy, and then compared the fatigue relief degree of two groups. In addition, we used NCBI dbSNP and PharmGKB databases to select fatigue related genes and their SNPs. We collected peripheral blood from the included patients for SNPs typing, and recorded the efficacy of electroacupuncture to analyzed the correlation between different SNPs and therapeutic efficacy. The side effects of electroacupuncture treatment were also recorded. 76 patients in the electroacupuncture group and 48 patients in the control group were enrolled. In the electroacupuncture group, 63 patients (82.9%) experienced moderate to severe fatigue (BFI score > 3). After electroacupuncture treatment, the number of patients with a BFI score of > 3 was 46 (60.5%). Therefore, the fatigue symptoms of 26.9% patients were significantly improved (P < 0.05). In the control group, which did not receive electroacupuncture treatment, 40 of 48 patients had a BFI score of > 3. Following the same observation time used in the electroacupuncture group, 36 patients had a BFI score of > 3 points. Thus, fatigue was not significantly relieved in the control group (83.3% vs. 75.0%, P > 0.05). We included 56 patients in our analysis of the correlation between SNPs and electroacupuncture treatment effects. We divided the patients into an effective group and ineffective group according to therapeutic effects. Our results indicated that the effective rate of electroacupuncture treatment with IL1A rs3783550 AC and CC genotypes was higher than that with other genotypes (AC: 84.6%, CC: 81.8%, AA: 33.0%, P < 0.05). Similarly, the effective rate of electroacupuncture treatment with HTR1A rs6295 GG and CC genotypes was higher than that with other genotypes (GG: 63.0%, CC: 55.6%, GC: 18.2%, P < 0.05). However, no other genotypes were related to the effect of electroacupuncture treatment on fatigue. Our result showed that electroacupuncture has therapeutic effect on fatigue after adjuvant chemotherapy for breast cancer and the side effects are tolerable. In addition, IL1A rs3763550 and HTR1A rss6295 can predict the therapeutic effect of electroacupuncture on fatigue after adjuvant chemotherapy in breast cancer, which helps to better screen patients who can benefit from electroacupuncture treatment.


  • Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis

    by Yonghui Zheng, Guoshuang Shen, Chengrong Zhang, Xingfa Huo, Yuanfang Xin, Qianqian Fang, Yumei Guan, Fuxing Zhao, Dengfeng Ren, Zhen Liu, et al.

    Anti-human epidermal growth factor receptor-2 (anti-HER2) therapy has shown excellent efficacy in patients with HER2 overexpression and amplification. Although HER2 mutations are rarely expressed in several cancers, when they occur, they can activate the HER2 signaling pathway. In recent years, studies have shown that anti-HER2 drugs have promising efficacy in patients with HER2 mutations. Based on keywords, we searched databases, such as PubMed, Embase, and Cochrane Library, and the main conference abstracts. We extracted data on objective response rate (ORR), clinical benefit rate (CBR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) from studies on the efficacy of anti-HER2 therapies in patients with HER2-mutated cancers, and analyzed grade 3 or higher adverse events (AEs). We included 19 single-arm clinical studies and 3 randomized controlled trials (RCTs), containing a total of 1017 patients with HER2 mutations, involving seven drugs and nine cancers, and 18 studies enrolled a high proportion of heavily pretreated patients who had received multiple lines of therapy. Our results showed pooled ORR and CBR of 25.0% (range, 3.8–72.7%; 95% CI, 18–32%) and 36.0% (range, 8.3–63.0%; 95% CI, 31–42%) for anti-HER2 therapy in HER2-mutated cancers. The pooled median PFS, OS, DOR were 4.89 (95% CI, 4.16–5.62), 12.78 (95% CI, 10.24–15.32), and 8.12 (95% CI, 6.48–9.75) months, respectively. In a subgroup analysis, we analyzed the ORR for different cancers, showing 27.0, 25.0, 23.0, and 16.0% for breast, lung, cervical, and biliary tract cancers, respectively. ORR analyses were performed for different drugs as monotherapy or in combination, showing 60.0% for trastuzumab deruxtecan (T-DXd), 31.0% for pyrotinib, 26.0% for neratinib combined with trastuzumab, 25.0% for neratinib combined with fulvestrant, 19.0% for trastuzumab combined with pertuzumab, and 16.0% for neratinib. In addition, we found that diarrhoea, neutropenia, and thrombocytopenia were the most common grade ≥ 3 AEs associated with anti-HER2 therapeutic agents. In this meta-analysis of heavily pretreated patients with HER2 mutations, anti-HER2 therapies, DS-8201 and trastuzumab emtansine, showed promising efficacy and activity. Anti-HER2 therapies showed different efficacies in different or the same cancer settings and all had a tolerable safety profile.